jump to content jump to footer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

mint Lesion: lesion categorization under the radiologic recurrence criteria for adjuvant trials
Radiologic recurrence criteria for adjuvant clinical trials in bladder cancer
Radiologic Recurrence Criteria for Adjuvant Clinical Trials in Bladder Cancer
After radical surgery, there is no measurable disease left to follow. A consensus framework defines when a finding on a surveillance scan counts as…
Read more
Radiologist reviewing a glioma MRI case in mint Lesion, with AI-based brain tumor segmentation from Snke (in development)
Consistent Glioma MRI Reporting with mint Lesion
In neuro-oncology, imaging assessments directly shape treatment decisions. For example, under RANO 2.0, whether a follow-up MRI is classified as…
Read more
Portrait of Ralf Heyder, head of the NUM Coordination Office at Charité, interviewed at the RACOON Research Days in Tübingen
Ralf Heyder, head of the NUM Coordination Office at Charité, interviewed at the RACOON Research Days in Tübingen
RACOON in the Network University Medicine – Ralf Heyder on collaborative imaging research
How Germany’s university hospitals built a shared platform for radiological imaging data, and what comes next In early October 2026, representatives…
Read more
scroll-top